Dr. James Chen receives Cancer Research Institute Award for groundbreaking discoveries on innate immunity
Biochemist Dr. Zhijian "James" Chen receives the 2020 William B. Coley Award in recognition for his work on the cGAS-STING pathway and its potential to improve cancer immunotherapies.
T cells may hold key to detecting early-stage cancer
Dr. Bo Li, Assistant Professor of Bioinformatics at UTSW, and colleagues have developed a deep learning system designed to detect subtle changes in T cells as a means for recognizing cancer in its earlist stage, when it's most easily treated.
Joint KCP and Cleveland Clinic study shows how pancreatic spread influences course of treatment
Researchers at UT Southwestern and the Cleveland Clinic unveil unique biology of kidney cancer that metastasizes to the pancreas, noting how and why it responds to TKIs but not immunotherapy. Press Release
Simmons Cancer Center elected to National Comprehensive Cancer Network
As a member of the NCCN, UT Southwestern Medical Center's Simmons Cancer Center faculty join faculty from 30 other top cancer institutions in the U.S. to develop NCCN Clinical Practice Guidelines, a recognized standard for clinical cancer care. Press Release
Leading kidney cancer experts gather in Dallas for 6th annual EAB meeting
Members of the KCP Scientific Advisory Board meet with members of the SPORE Executive Committee and other KCP members to discuss research initiatives. Highlights of this year's meeting included the KCP SPORE renewal.
UT Southwestern investigators awarded funding for AI research
Dr. Vitaly Margulis, Professor of Urology, and Dr. Xiaosong Meng, Urologic Oncology Fellow, are among five recipients selected from four institutions - the National Institutes of Health, Thomas Jefferson University, M.D. Anderson Cancer Center and UT Southwestern Medical Center - to receive funding from the Kidney Cancer Research Alliance (KCCure) for groundbreaking kidney cancer research. Drs. Margulis and Meng are exploring the use of deep machine learning to identify aggressive tumor characteristics in renal cell carcinoma. Press Release
RADVAX clinical trial among pioneering research spotlighted at ASCO GU 2020
Dr. Hans Hammers, KCP Co-Leader for Clinical Research, presents results from UT Southwestern's clinical trial combining dual immune checkpoint inhibitors and stereotactic ablative radiotherapy (SBRT) for metastatic kidney cancer at the Oral Abstract Session. The RADVAX trial, as it's known, uses SBRT as an in situ vaccine to improve the effectiveness of immunotherapy. Article
Tumor dependency on HIF-2 pathway may prove Achilles heel for kidney cancer
In a newly published study revealing the underlying efficacy of HIF-2 inhibitor drugs, investigators at UT Southwestern have discovered a potential Achilles heel for kidney cancer. Clinical trial findings identified a cancer core dependency on HIF-2, a protein complex that plays a key role in the activation of genes responsible for cancer growth. In response to the drug's ability to disable HIF-2, tumors developed a resistance in the form of a mutation in the protein binding pocket where the drug is delivered, thereby preventing access to it. The finding suggests the critical role HIF-2 plays in the progression of kidney cancer and the extent to which tumors will safeguard it. Press Release
Researchers identify promising new kidney cancer target
Recent KCP recruit, Dr. Qing Zhang, Associate Professor of Pathology, and colleagues identify a selective vulnerability in VHL-mutant kidney cancer cells that could be exploited for therapy. Press Release
D Magazine Innovation Awards ceremony
Dr. James Brugarolas represents the Kidney Cancer Program at the inaugural Innovation Awards event, hosted by D Magazine and DCEO. The KCP was among five finalists recognized for Innovation in Healthcare. In total, 47 North Texas companies, organizations and entrepreneurs were honored across 13 award categories. (Image: Dr. James Brugarolas, director of the Kidney Cancer Program, with Gillea Allison, president of D Magazine Partners.)